Metropolis Healthcare Intrinsic Value
METROPOLIS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹608.94 | ₹487.15 - ₹730.73 | -70.0% | EPS: ₹40.68, Sector P/E: 12x |
| Book Value Method | asset | ₹1335.00 | ₹1201.50 - ₹1468.50 | -34.2% | Book Value/Share: ₹1335.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1376.00 | ₹1238.40 - ₹1513.60 | -32.2% | Revenue/Share: ₹1720.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹2481.20 | ₹2233.08 - ₹2729.32 | +22.2% | EBITDA: ₹436.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹2116.99 | ₹1693.59 - ₹2540.39 | +4.3% | CF Growth: 1.4%, Discount: 15% |
| PEG Ratio Method | growth | ₹608.94 | ₹548.05 - ₹669.83 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹608.94 | ₹548.05 - ₹669.83 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹2968.00 | ₹2671.20 - ₹3264.80 | +46.2% | ROE: 15.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1105.41 | ₹994.87 - ₹1215.95 | -45.5% | EPS: ₹40.68, BVPS: ₹1335.00 |
Want to compare with current market value? Check METROPOLIS share price latest .
Valuation Comparison Chart
METROPOLIS Intrinsic Value Analysis
What is the intrinsic value of METROPOLIS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Metropolis Healthcare (METROPOLIS) is ₹1335.00 (median value). With the current market price of ₹2029.80, this represents a -34.2% variance from our estimated fair value.
The valuation range spans from ₹608.94 to ₹2968.00, indicating ₹608.94 - ₹2968.00.
Is METROPOLIS undervalued or overvalued?
Based on our multi-method analysis, Metropolis Healthcare (METROPOLIS) appears to be trading above calculated value by approximately 34.2%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.45 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.40 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 15.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.92x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Metropolis Healthcare
Additional stock information and data for METROPOLIS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹263 Cr | ₹164 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹264 Cr | ₹220 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹247 Cr | ₹247 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹253 Cr | ₹-115 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹249 Cr | ₹249 Cr | Positive Free Cash Flow | 8/10 |